On August 14, 2024, Kamada Ltd. (KMDA) announced financial results for the second quarter of 2024. Revenues for the second quarter of 2024 were $42.5 million, which was a 13% increase compared to the second quarter of 2023. Adjusted EBITDA was $9.1 million, which was a 51% increase from the second quarter of 2023. The company reiterated its full year revenue guidance to $158 million to $162 million and adjusted EBITDA of $28 million to $32 million. Patient enrollment continues in the pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin. After filing an IND amendment with the FDA last quarter that included a revised Statistical Analysis Plan (SAP) and study protocol, the company is waiting to receive FDA feedback that may allow for the acceleration of the program.
